Journal Article (Review Article)

DKFZ-2023-00541

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Next Generation Radiotheranostics Promoting Precision Medicine.

Pomykala, K. L. ; Hadaschik, B. A. ; Sartor, O. ; Gillessen, S. ; Sweeney, C. J. ; Maughan, T. ; Hofman, M. S. ; Herrmann, M.DKFZ*

2023
Elsevier Amsterdam [u.a.

This record in other databases:  

Please use a persistent id in citations: doi:10.1016/j.annonc.2023.03.001

Abstract: Radiotheranostics is a field of rapid growth with some approved treatments including 131I for thyroid cancer, 223Ra for osseous metastases, 177Lu-Dotatate for neuroendocrine tumors, and 177Lu-PSMA for prostate cancer, and several more under investigation. In this review, we will cover the fundamentals of radiotheranostics, the key clinical studies that have led to current success, future developments with new targets, radionuclides and platforms, challenges with logistics and reimbursement and, lastly, forthcoming considerations regarding dosimetry, identifying the right line of therapy, artificial intelligence and more.

Keyword(s): (177)Lu-Dotatate ; (177)Lu-PSMA ; endoradiotherapy ; positron emission tomography ; radiotheranostics ; targeted radioligand therapy

Note: 2023 Jun;34(6):507-519

---

Contributing Institute(s):

1. DKTK ED ES zentral (ED01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2023

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 50 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---